Zhejiang Doer Biologics (Doer Bio) has concluded subject enrolment in a Phase Ib/IIa clinical trial of DR10624 in obese patients with modest hypertriglyceridemia in New Zealand.
A long-acting tri-specific agonist, DR10624 is directed at the fibroblast growth factor 21 receptor (FGF21R), glucagon-like peptide-1 receptor (GLP-1R), and glucagon receptor (GCGR).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The placebo-controlled, randomised, double-blind trial will assess the tolerability, safety, pharmacokinetics and pharmacodynamics of DR10624 in adults with a body mass index (BMI) of 30kg/m² to 45kg/m² and modest hypertriglyceridemia.
Four varying doses of DR10624 will be assessed in the trial.
The trial subjects will receive subcutaneous injections of DR10624 once a week or a placebo for 12 weeks.
The impact of DR10624 on serum lipids, liver fat, and body weight will also be assessed in the trial.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDoer Bio founder and CEO Yanshan Huang said: “DR10624 is a novel FIC tri-specific biotherapeutic that specifically agonises FGF21R, GLP-1R, and GCGR. Utilising Doer Bio’s proprietary MultipleBody platform technology, DR10624 is designed and engineered to exhibit balanced activity for various metabolic diseases.
“In our preclinical studies, DR10624 has shown outstanding potency on body weight reduction, blood lipid normalisation, and liver function improvement.”
The company plans to report the data from the clinical trial earlier next year.
Doer Bio chief operating officer Yongliang Fang said: “We’re excited to announce the successful completion of patient enrolment for our Phase Ib/IIa clinical trial of DR10624 in New Zealand. This achievement marks an important milestone in our clinical translation of DR10624 globally.
“There is a growing unmet medical need for patients suffering from obesity and hypertriglyceridemia. We look forward to developing DR10624 as a potential treatment for patients struggling with metabolic dysfunction.”
